David S Shulman, MD
Dana-Farber Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name David S Shulman, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:28 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06068075 · Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARDDana-Farber Cancer Institute · active not recruiting · Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue · principal investigator
- Ph1NCT03654716 · Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric CancerDana-Farber Cancer Institute · completed · Leukemia, Brain Tumor, Solid Tumor · principal investigator
- Ph1NCT02909777 · Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or LymphomaDana-Farber Cancer Institute · completed · Lymphoma, Neuroblastoma, Brain Tumor · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in neuroblastoma.